Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection
- PMID: 36658755
- DOI: 10.1002/pros.24485
Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection
Abstract
Background: Androgens may play a role in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and host responses as the virus is dependent on the androgen-regulated protein transmembrane serine protease 2 for cell entry. Studies have indicated that prostate cancer patients receiving androgen deprivation therapy (ADT) are at reduced risk of SARS-CoV-2 infection and serious complications compared with patients without ADT, but data are inconsistent.
Methods: A total of 655 prostate cancer patients who were under surveillance at two urology departments in Sweden on April 1, 2020 were included in the study as well as 240 patients with benign prostatic hyperplasia (BPH). At follow-up early in 2021, the participants completed a questionnaire containing information about symptoms compatible with coronavirus disease 2019 (COVID-19). Blood samples were also collected for the assessment of SARS-CoV-2 IgG antibodies (SARS-CoV-2 Total; Siemens). We used multivariable logistic regression models to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between ADT and the risk of SARS-CoV-2 infection.
Results: The cumulative incidence of SARS-CoV-2 seropositivity was 13.4% among patients receiving ADT and 10.4% among patients without ADT. After adjusting for potential confounders, we observed no differences in symptoms or risk of SARS-CoV-2 infection between patients with and without ADT (OR: 0.98; 95% CI: 0.52-1.85). Higher body mass index, Type 1 diabetes, and prostate cancer severity, defined by high Gleason score (8-10; OR: 2.06; 95% CI: 1.04-4.09) or elevated levels of prostate-specific antigen (>20 µg/l; OR: 2.15; 95% CI: 1.13-4.07) were associated with increased risk of SARS-CoV-2 infection. Overall, the risk of SARS-CoV-2 infection was not higher among men with prostate cancer than among men with BPH.
Conclusions: Our results do not support the hypothesis that ADT use in prostate cancer patients reduces the risk or symptom severity of SARS-CoV-2 infection or that prostate cancer patients are at increased risk of COVID-19 compared with men without prostate cancer.
Keywords: COVID-19; SARS-CoV-2; androgen deprivation therapy; prostate cancer.
© 2023 The Authors. The Prostate published by Wiley Periodicals LLC.
Similar articles
-
Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis.World J Urol. 2022 Apr;40(4):907-914. doi: 10.1007/s00345-021-03810-6. Epub 2021 Sep 3. World J Urol. 2022. PMID: 34477955 Free PMC article.
-
Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer.Asian J Androl. 2023 May-Jun;25(3):366-374. doi: 10.4103/aja202246. Asian J Androl. 2023. PMID: 35915542 Free PMC article.
-
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).Ann Oncol. 2020 Aug;31(8):1040-1045. doi: 10.1016/j.annonc.2020.04.479. Epub 2020 May 6. Ann Oncol. 2020. PMID: 32387456 Free PMC article.
-
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.JAMA Netw Open. 2021 Nov 1;4(11):e2134330. doi: 10.1001/jamanetworkopen.2021.34330. JAMA Netw Open. 2021. PMID: 34767021 Free PMC article.
-
Relationship Between Androgen Deprivation Therapy for Prostate Cancer and Risk of SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis.J Korean Med Sci. 2022 Aug 8;37(31):e237. doi: 10.3346/jkms.2022.37.e237. J Korean Med Sci. 2022. PMID: 35942555 Free PMC article.
Cited by
-
Independent association between prostate-specific antigen nadir and PSA progression-free survival in first-line abiraterone acetate treatment in castration-resistant prostate cancer patients: a pilot study.Front Oncol. 2024 Jun 4;14:1348324. doi: 10.3389/fonc.2024.1348324. eCollection 2024. Front Oncol. 2024. PMID: 38898958 Free PMC article.
-
Antiandrogens as Therapies for COVID-19: A Systematic Review.Cancers (Basel). 2024 Jan 10;16(2):298. doi: 10.3390/cancers16020298. Cancers (Basel). 2024. PMID: 38254788 Free PMC article. Review.
References
REFERENCES
-
- Lawton G. Men hit harder by covid-19. New Sci. 2020;246:8.
-
- Borges do Nascimento IJ, Cacic N, Abdulazeem HM, et al. Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med. 2020;9:941.
-
- Wambier CG, Goren A, Vaño-Galván S, et al. Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res. 2020;81:771-776.
-
- Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and COVID-19: serendipity or opportunity for intervention? Cancer Discov. 2020;10:779-782.
-
- Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol. 2020;31:1040-1045.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous